• DCPS as an m7G Biomarker in Diabetic Foot Ulcer Epithelial R

  2026-05-29

  This study identifies the decapping scavenger enzyme (DCPS) as a novel N7-methylguanosine (m7G)-related biomarker that regulates epithelial cell function and wound healing in diabetic foot ulcers (DFU). The findings advance our understanding of RNA methylation in chronic wound pathophysiology and highlight DCPS as a potential diagnostic and therapeutic target.

• Trichostatin A (TSA): Protocols and QC for Epigenetic Studie

  2026-05-29

  Trichostatin A (TSA) is a well-characterized HDAC inhibitor for researchers investigating epigenetic regulation, particularly in cancer and differentiation models. This product is optimized for cell-based and animal studies requiring controlled histone acetylation modulation. It is not suitable for workflows requiring aqueous solubility or long-term solution stability.

• Protoporphyrin IX: Bridging Photodynamic Therapy and Ferropt

  2026-05-28

  Explore the scientific role of Protoporphyrin IX as a photodynamic compound at the intersection of heme biosynthesis, iron metabolism, and ferroptosis resistance. This article delivers a unique, application-focused perspective for researchers seeking advanced workflows in cancer and metabolic disease.

• THZ1 and the Precision Targeting of CDK7: New Directions in

  2026-05-28

  Explore how THZ1, a covalent CDK7 inhibitor, is redefining transcription regulation in cancer biology. This article unveils mechanistic depth, unique resistance insights, and advanced applications for T-ALL research.

• Fumagillin in Translational Oncology and Antiparasitic Resea

  2026-05-27

  Explore how Fumagillin, a methionine aminopeptidase-2 inhibitor, uniquely bridges cancer and antiparasitic research. This article offers an integrated scientific and practical guide for applying Fumagillin across angiogenesis and emerging protozoan infection models.

• Crizotinib hydrochloride (B3608): Reliable ALK Kinase Inhibi

  2026-05-27

  Crizotinib hydrochloride (SKU B3608) is a rigorously validated ALK kinase inhibitor, designed for reproducible inhibition of oncogenic pathways in advanced cancer biology research. This article demonstrates practical solutions to common laboratory challenges—such as assay variability and microenvironmental complexity—using scenario-driven analysis, with evidence-based advice for optimizing cell-based assays and model systems.

• Endothelial STING-JAK1 Axis: Normalizing Tumor Vasculature a

  2026-05-26

  This study uncovers a pivotal mechanism by which endothelial STING, interacting with JAK1, promotes tumor vessel normalization and enhances antitumor immunity by facilitating CD8+ T cell infiltration. The findings clarify endothelial-specific pathways downstream of interferon signaling, with direct implications for designing next-generation STING agonists and vascular-targeted therapies.

• Cy3 NHS Ester (Non-Sulfonated): Technical Guide for Biomolec

  2026-05-26

  Cy3 NHS ester (non-sulfonated) enables efficient fluorescent labeling of proteins, peptides, and oligonucleotides via amine coupling, supporting sensitive detection in biomedical imaging and analytical workflows. This dye is not suitable for fully aqueous protocols or delicate proteins sensitive to organic co-solvents. Follow recommended solvent and storage practices to ensure labeling efficiency and reproducibility.

• EZ Cap™ Cre mRNA (m1Ψ): Reliable Gene Editing for Functional

  2026-05-25

  This article addresses real-world laboratory challenges in cell-based assays and gene editing, demonstrating how EZ Cap™ Cre mRNA (m1Ψ) (SKU R1030) delivers reproducible, high-efficiency Cre recombinase expression with minimized immunogenicity. Scenario-driven Q&A blocks, grounded in literature and quantitative analysis, guide researchers in protocol optimization, data interpretation, and vendor selection for robust biomedical workflows.

• Chlorpromazine HCl (SKU B1480): Scenario-Driven Lab Solution

  2026-05-25

  This article provides an evidence-based exploration of Chlorpromazine HCl (SKU B1480) for cell viability, endocytosis, and cytotoxicity assays. Through five real-world laboratory scenarios, we highlight how APExBIO's Chlorpromazine HCl offers reproducible, workflow-friendly performance for biomedical researchers seeking robust dopamine receptor antagonism and precise pathway inhibition.

• A-1331852: Advanced BCL-XL Inhibitor Workflows for Apoptosis

  2026-05-24

  A-1331852 stands out as a next-generation BCL-XL inhibitor, enabling highly selective apoptosis induction in BCL-XL–dependent cancer cells. Its superior potency, workflow-friendly solubility, and proven synergy in senolytic strategies offer researchers a robust tool for dissecting apoptotic pathways and optimizing preclinical cancer models.

• Dextrose (D-glucose): Precision Tools for Metabolic Research

  2026-05-23

  APExBIO’s Dextrose (D-glucose) delivers unrivaled purity and solubility for cell culture, metabolic assays, and tumor microenvironment studies. This guide translates recent breakthroughs in hypoxia and immunometabolism into actionable protocols and troubleshooting strategies, empowering robust, reproducible experimental outcomes.

• DiscoveryProbe™ Protease Inhibitor Library: Evidence & Integ

  2026-05-22

  The DiscoveryProbe Protease Inhibitor Library offers 825 validated, cell-permeable inhibitors for diverse protease inhibition studies. It enables high-throughput and high-content screening across cancer, apoptosis, and infectious disease research. This article synthesizes atomic evidence, protocol parameters, and application boundaries for robust, machine-readable reference.

• Cyclic di-GMP: Transforming Biofilm and Immunity Research

  2026-05-22

  Explore the dual mechanistic role of cyclic di-GMP as both a bacterial antitoxin and STING pathway agonist, and discover translational strategies for leveraging this intracellular second messenger in biofilm persistence, genome stability, and immune modulation research. This thought-leadership article bridges breakthrough evidence, protocol guidance, and actionable insight for advanced infection biology and cancer immunotherapy studies, with practical recommendations for product selection and implementation.

• Verbascoside: Strategic PKC/NF-κB Inhibition in Bone Researc

  2026-05-21

  This thought-leadership article explores how Verbascoside, a potent PKC/NF-κB inhibitor from APExBIO, is redefining osteoclastogenesis research by targeting critical signaling pathways. Integrating mechanistic insights from recent landmark studies, it offers translational researchers actionable protocol guidance, competitive context, and a forward-looking perspective on bone metabolism and inflammation research.

459 records 17/31 page Previous Next First page 上5页 1617181920 下5页 Last page